Eargo Competitors

Eargo (NASDAQ:EAR) and MSA Safety (NYSE:MSA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

77.2% of MSA Safety shares are held by institutional investors. 7.0% of MSA Safety shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Eargo and MSA Safety, as reported by MarketBeat.

Eargo currently has a consensus price target of $48.00, indicating a potential upside of 2.85%. MSA Safety has a consensus price target of $151.50, indicating a potential downside of 2.23%. Given Eargo's stronger consensus rating and higher probable upside, equities research analysts plainly believe Eargo is more favorable than MSA Safety.

Earnings and Valuation

This table compares Eargo and MSA Safety's revenue, earnings per share and valuation.

MSA Safety has higher revenue and earnings than Eargo.

Profitability

This table compares Eargo and MSA Safety's net margins, return on equity and return on assets.

Summary

MSA Safety beats Eargo on 6 of the 9 factors compared between the two stocks.

Avanos Medical (NYSE:AVNS) and Eargo (NASDAQ:EAR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Avanos Medical and Eargo's net margins, return on equity and return on assets.

Institutional and Insider Ownership

94.8% of Avanos Medical shares are held by institutional investors. 1.5% of Avanos Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Avanos Medical and Eargo's gross revenue, earnings per share and valuation.

Eargo has lower revenue, but higher earnings than Avanos Medical.

Analyst Recommendations

This is a breakdown of recent recommendations for Avanos Medical and Eargo, as reported by MarketBeat.com.

Avanos Medical currently has a consensus target price of $50.00, indicating a potential upside of 11.16%. Eargo has a consensus target price of $48.00, indicating a potential upside of 2.85%. Given Avanos Medical's higher possible upside, equities analysts plainly believe Avanos Medical is more favorable than Eargo.

Summary

Avanos Medical beats Eargo on 7 of the 9 factors compared between the two stocks.

Eargo (NASDAQ:EAR) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

54.8% of Establishment Labs shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Eargo and Establishment Labs, as provided by MarketBeat.

Eargo currently has a consensus price target of $48.00, indicating a potential upside of 2.85%. Establishment Labs has a consensus price target of $46.00, indicating a potential downside of 31.09%. Given Eargo's stronger consensus rating and higher probable upside, equities research analysts plainly believe Eargo is more favorable than Establishment Labs.

Valuation and Earnings

This table compares Eargo and Establishment Labs' top-line revenue, earnings per share (EPS) and valuation.

Eargo has higher earnings, but lower revenue than Establishment Labs.

Profitability

This table compares Eargo and Establishment Labs' net margins, return on equity and return on assets.

Summary

Eargo beats Establishment Labs on 6 of the 9 factors compared between the two stocks.

Inogen (NASDAQ:INGN) and Eargo (NASDAQ:EAR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Insider & Institutional Ownership

95.1% of Inogen shares are owned by institutional investors. 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Inogen and Eargo, as reported by MarketBeat.com.

Inogen currently has a consensus target price of $63.00, indicating a potential downside of 0.25%. Eargo has a consensus target price of $48.00, indicating a potential upside of 2.85%. Given Eargo's stronger consensus rating and higher probable upside, analysts clearly believe Eargo is more favorable than Inogen.

Valuation & Earnings

This table compares Inogen and Eargo's top-line revenue, earnings per share and valuation.

Inogen has higher revenue and earnings than Eargo.

Profitability

This table compares Inogen and Eargo's net margins, return on equity and return on assets.

Summary

Inogen beats Eargo on 5 of the 9 factors compared between the two stocks.

Sientra (NASDAQ:SIEN) and Eargo (NASDAQ:EAR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Profitability

This table compares Sientra and Eargo's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings for Sientra and Eargo, as reported by MarketBeat.

Sientra presently has a consensus target price of $10.00, indicating a potential upside of 44.93%. Eargo has a consensus target price of $48.00, indicating a potential upside of 2.85%. Given Sientra's higher probable upside, equities research analysts plainly believe Sientra is more favorable than Eargo.

Insider and Institutional Ownership

71.0% of Sientra shares are owned by institutional investors. 2.8% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Sientra and Eargo's gross revenue, earnings per share (EPS) and valuation.

Eargo has lower revenue, but higher earnings than Sientra.

Summary

Sientra beats Eargo on 4 of the 7 factors compared between the two stocks.

Invacare (NYSE:IVC) and Eargo (NASDAQ:EAR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.

Profitability

This table compares Invacare and Eargo's net margins, return on equity and return on assets.

Insider & Institutional Ownership

96.7% of Invacare shares are held by institutional investors. 3.2% of Invacare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Invacare and Eargo's revenue, earnings per share and valuation.

Eargo has lower revenue, but higher earnings than Invacare.

Analyst Recommendations

This is a summary of recent ratings and price targets for Invacare and Eargo, as provided by MarketBeat.

Invacare presently has a consensus price target of $17.00, suggesting a potential upside of 99.53%. Eargo has a consensus price target of $48.00, suggesting a potential upside of 2.85%. Given Invacare's higher possible upside, equities research analysts clearly believe Invacare is more favorable than Eargo.